John A. Ascher

8.4k total citations · 4 hit papers
60 papers, 6.1k citations indexed

About

John A. Ascher is a scholar working on Psychiatry and Mental health, Pharmacology and Experimental and Cognitive Psychology. According to data from OpenAlex, John A. Ascher has authored 60 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Psychiatry and Mental health, 14 papers in Pharmacology and 12 papers in Experimental and Cognitive Psychology. Recurrent topics in John A. Ascher's work include Schizophrenia research and treatment (14 papers), Bipolar Disorder and Treatment (13 papers) and Treatment of Major Depression (12 papers). John A. Ascher is often cited by papers focused on Schizophrenia research and treatment (14 papers), Bipolar Disorder and Treatment (13 papers) and Treatment of Major Depression (12 papers). John A. Ascher collaborates with scholars based in United States, United Kingdom and Netherlands. John A. Ascher's co-authors include Joseph R. Calabrese, Charles L. Bowden, Sharyn R. Batey, Cort A. Pedersen, Arthur J. Prange, Roy H. Perlis, Joseph A. Johnston, G. David Rudd, Trisha L. Houser and Rafe Donahue and has published in prestigious journals such as Science, The Lancet and American Journal of Psychiatry.

In The Last Decade

John A. Ascher

59 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Double-Blind Placebo-Controlled Study of Lamotrigine Monotherapy in Outpatients With Bipolar I Depression

1999 681 citations Joseph R. Calabrese, Charles L. Bowden et al. The Journal of Clinical Psychiatry profile →
Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial

2016 632 citations Robert M. Anthenelli, Neal L. Benowitz et al. The Lancet profile →
Oxytocin Induces Maternal Behavior in Virgin Female Rats

1982 594 citations John A. Ascher et al. profile →
Bupropion: a review of its mechanism of antidepressant activity.

1995 561 citations John A. Ascher et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John A. Ascher United States	32	3.1k	1.4k	937	781	743	60	6.1k
Prakash S. Masand United States	42	2.5k 0.8×	1.6k 1.1×	617 0.7×	310 0.4×	477 0.6×	225	5.5k
Ashwin A. Patkar United States	44	2.0k 0.6×	1.8k 1.3×	933 1.0×	608 0.8×	641 0.9×	282	7.2k
Miquel Bernardo Spain	49	5.5k 1.8×	994 0.7×	702 0.7×	370 0.5×	777 1.0×	406	8.8k
Valeria Mondelli United Kingdom	55	3.5k 1.1×	1.1k 0.8×	859 0.9×	621 0.8×	899 1.2×	232	10.8k
Katherine J. Aitchison United Kingdom	44	1.9k 0.6×	1.1k 0.8×	364 0.4×	346 0.4×	816 1.1×	159	6.0k
Del D. Miller United States	52	5.0k 1.6×	852 0.6×	503 0.5×	394 0.5×	545 0.7×	135	8.4k
John Rotrosen United States	53	3.7k 1.2×	1.0k 0.7×	849 0.9×	719 0.9×	593 0.8×	282	10.4k
Charles M. Beasley United States	48	5.8k 1.9×	2.5k 1.8×	397 0.4×	397 0.5×	757 1.0×	145	8.1k
Alan J. Gelenberg United States	49	3.5k 1.1×	2.7k 1.9×	530 0.6×	553 0.7×	1.7k 2.2×	158	8.7k
Russell T. Joffe Canada	53	3.6k 1.2×	1.7k 1.2×	379 0.4×	543 0.7×	1.6k 2.1×	210	9.1k

Countries citing papers authored by John A. Ascher

Since Specialization

Citations

This map shows the geographic impact of John A. Ascher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John A. Ascher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John A. Ascher more than expected).

Fields of papers citing papers by John A. Ascher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John A. Ascher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John A. Ascher. The network helps show where John A. Ascher may publish in the future.

Co-authorship network of co-authors of John A. Ascher

This figure shows the co-authorship network connecting the top 25 collaborators of John A. Ascher. A scholar is included among the top collaborators of John A. Ascher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John A. Ascher. John A. Ascher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ascher, John A., et al.. (2018). Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation. Drugs - Real World Outcomes. 5(3). 181–191. 2 indexed citations

Anthenelli, Robert M., Neal L. Benowitz, Robert West, et al.. (2016). Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. The Lancet. 387(10037). 2507–2520. 632 indexed citations breakdown →

Silberstein, Stephen D., et al.. (2012). Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis. Cephalalgia. 33(2). 101–111. 36 indexed citations

Brittain, Claire, Donavon J. McConn, Laura Iavarone, et al.. (2010). Dose‐Related Reduction in Bupropion Plasma Concentrations by Ritonavir. The Journal of Clinical Pharmacology. 50(10). 1180–1187. 31 indexed citations

Weisler, Richard H., Joseph R. Calabrese, Charles L. Bowden, et al.. (2007). Discovery and development of lamotrigine for bipolar disorder: A story of serendipity, clinical observations, risk taking, and persistence. Journal of Affective Disorders. 108(1-2). 1–9. 36 indexed citations

Calabrese, Joseph R., Charles L. Bowden, Gary Sachs, et al.. (2003). A Placebo-Controlled 18-Month Trial of Lamotrigine and Lithium Maintenance Treatment in Recently Depressed Patients With Bipolar I Disorder. The Journal of Clinical Psychiatry. 64(9). 1013–1024. 454 indexed citations

Weihs, Karen L., Trisha L. Houser, Sharyn R. Batey, et al.. (2002). Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biological Psychiatry. 51(9). 753–761. 54 indexed citations

Rush, A. John, Sharyn R. Batey, Rafe Donahue, et al.. (2001). Does pretreatment anxiety predict response to either bupropion SR or sertraline?. Journal of Affective Disorders. 64(1). 81–87. 24 indexed citations

Weihs, Karen L., Edmund C. Settle, Sharyn R. Batey, et al.. (2000). Bupropion Sustained Release Versus Paroxetine for the Treatment of Depression in the Elderly. The Journal of Clinical Psychiatry. 61(3). 196–202. 110 indexed citations

10.

Segraves, Robert, Richard J. Kavoussi, Arlene R. Hughes, et al.. (2000). Evaluation of Sexual Functioning in Depressed Outpatients: A Double-Blind Comparison of Sustained-Release Bupropion and Sertraline Treatment. Journal of Clinical Psychopharmacology. 20(2). 122–128. 72 indexed citations

11.

Calabrese, Joseph R., Trisha Suppes, Charles L. Bowden, et al.. (2000). A Double-Blind, Placebo-Controlled, Prophylaxis Study of Lamotrigine in Rapid-Cycling Bipolar Disorder. The Journal of Clinical Psychiatry. 61(11). 841–850. 365 indexed citations

12.

Bowden, Charles L., Joseph R. Calabrese, Susan L. McElroy, et al.. (1999). The efficacy of lamotrigine in rapid cycling and non–rapid cycling patients with bipolar disorder. Biological Psychiatry. 45(8). 953–958. 115 indexed citations

13.

Croft, Harry A., Edmund C. Settle, Trisha L. Houser, et al.. (1999). A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clinical Therapeutics. 21(4). 643–658. 188 indexed citations

14.

Bowden, Charles L., Susan L. McElroy, Paul E. Keck, et al.. (1999). Spectrum of Activity of Lamotrigine in Treatment-Refractory Bipolar Disorder. American Journal of Psychiatry. 156(7). 1019–1023. 126 indexed citations

15.

Reimherr, Frederick W., Lynn Cunningham, Sharyn R. Batey, Joseph A. Johnston, & John A. Ascher. (1998). A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients. Clinical Therapeutics. 20(3). 505–516. 61 indexed citations

16.

Calabrese, Joseph D., C.L. Bowden, Susan L. McElroy, et al.. (1997). Lamictal Monotherapy in the treatment of bipolar disorder. European Neuropsychopharmacology. 1002(7). 3 indexed citations

17.

Kavoussi, Richard J., Robert Segraves, Arlene R. Hughes, John A. Ascher, & Joseph A. Johnston. (1997). Double-Blind Comparison of Bupropion Sustained Release and Sertraline in Depressed Outpatients. The Journal of Clinical Psychiatry. 58(12). 532–537. 122 indexed citations

18.

Ali, Hassan H., Cynthia A. Lien, Thomas A. Witkowski, et al.. (1996). Efficacy and safety of divided dose administration of mivacurium for a 90-second tracheal intubation. Journal of Clinical Anesthesia. 8(4). 276–281. 12 indexed citations

19.

Margolin, Arthur, Thomas R. Kosten, S. Kelly Avants, et al.. (1995). A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug and Alcohol Dependence. 40(2). 125–131. 145 indexed citations

20.

White, H. L. & John A. Ascher. (1992). PRECLINICAL AND EARLY CLINICAL STUDIES WITH BW 1370U87, A REVERSIBLE COMPETITIVE MAO-A INHIBITOR. Clinical Neuropharmacology. 15. 343A–344A. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact